The study shows that industry-sponsored research was 33 percent more likely to find cost benefits of its drugs with threshold values between $50,000 and $150,000 compared to non-industry-sponsored research.
More than 70 percent of the 8,192 cost-effectiveness studies reported the studied drugs were more effective and costly. Among these 5,877 cost-effectiveness analyses, sponsorship bias was most heavy in drug interventions in model-based study designs.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
